Search
BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19.
Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
To generate a conceptual framework describing what is done to reduce the impact of chronic tinnitus on the lives of children and adolescents.
The effectiveness and safety profile of antiseptics in the treatment of chronic suppurative otitis media is uncertain
The aim of this Cochrane Review was to find out if hearing loss caused by noise at work is being prevented by current interventions
Our results indicate immediate priorities for health service planning and for strengthening of vital registration systems
Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting
Aboriginal children and children from lower socio-economic backgrounds were over-represented with OM-related hospitalizations but had fewer TTIs
PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses
To assess the relative effectiveness of topical versus systemic antibiotics for people with chronic suppurative otitis media